The eNose Company has developed the aeoNose, a portable breath analyzer designed to facilitate the early detection of various pathologies, including lung and colorectal cancers, as well as COVID-19. This innovative technology leverages the analysis of volatile organic compounds (VOCs) present in exhaled breath, which can change in composition due to the presence of disease. The aeoNose has undergone extensive development and validation, including multi-center studies in collaboration with prominent hospitals and medical professionals in the Netherlands and Switzerland. These studies have demonstrated the device's potential to accurately identify and classify diseases based on unique "breath prints," with the aim of providing a non-invasive, cost-effective alternative to traditional diagnostic methods.

In addition to its applications in cancer detection, the aeoNose is also being validated for use in identifying COVID-19 infections, showcasing its versatility in addressing various health concerns. The company emphasizes the importance of quick and accurate diagnostics, aiming to reduce the reliance on more invasive testing procedures. With ongoing research and validation efforts, the aeoNose is positioned to become a valuable tool in clinical settings, potentially transforming how diseases are diagnosed and monitored through simple breath analysis.

Netherlands

Develop diagnostic tools for screening of diseases through exhaled breath.

The eNose Company

Company Details